Antibiotic Treatment Pipeline for Clostridioides difficile Infection (CDI): A Wide Array of Narrow-Spectrum Agents

AbstractPurpose of ReviewClostridioides difficile infection (CDI) represents a major burden on the U.S. healthcare system. Despite the U.S. Food and Drug Administration (FDA) approval of fidaxomicin in 2011, observed rates of clinical cure and CDI recurrence suggest there is room to improve. As a result, there are many antibiotic treatments in the developmental pipeline for CDI. The purpose of this focused review is to summarize these antibiotic therapies in all stages of development.Recent FindingsHere, we discuss 10 antibiotics in development, including three that have completed phase II trials, five in phase II trials, and two still undergoing preclinical trials.SummaryThe antibiotic treatment pipeline for CDI contains a plethora of narrow-spectrum agents with unique mechanisms of action and potent activity againstC. difficile. Only ridinilazole, LFF571, and ramoplanin have completed phase II trials, and ridinilazole is the only antibiotic to begin recruitment for a phase III trial. While the future of CDI treatment appears bright, the healthcare community will have to await the results from phase III trials.
Source: Current Infectious Disease Reports - Category: Infectious Diseases Source Type: research